Impax Laboratories Appoints Mark A. Schlossberg as Senior Vice President and General Counsel
May 02 2011 - 10:30AM
Business Wire
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today
the appointment of Mark A. Schlossberg as Senior Vice President and
General Counsel. In this role, Mr. Schlossberg will report to
Impax’s President and Chief Executive Officer and be responsible
for all of Impax’s legal affairs.
Mr. Schlossberg brings over 25 years of legal experience to
Impax, including more than 11 in the healthcare industry. He joins
Impax from Amgen Inc., where he served as Vice President, Associate
General Counsel, responsible for the areas of corporate governance
and securities law, licensing, mergers and acquisitions, sales and
marketing and global operations. Prior to joining Amgen, he held
legal and business positions at Medtronic, Inc., and legal
positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie
Alexander & Ferdon. He earned a Bachelor of Sciences in
business administration and finance from the University of Southern
California and a Juris Doctor degree from Emory University.
Larry Hsu, Ph.D., president and CEO of Impax said, “We are very
pleased that Mark joins Impax as our General Counsel. He is an
accomplished executive with extensive legal and business leadership
experience. Impax has experienced significant growth the past
several years and his addition further enhances our management
team.”
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (“Impax”) is a technology based
specialty pharmaceutical company applying its formulation expertise
and drug delivery technology to the development of
controlled-release and specialty generics in addition to the
development of branded products. Impax markets its generic products
through its Global Pharmaceuticals division and markets its branded
products through the Impax Pharmaceuticals division. Additionally,
where strategically appropriate, Impax has developed marketing
partnerships to fully leverage its technology platform. Impax is
headquartered in Hayward, California, and has a full range of
capabilities in its Hayward, Philadelphia and Taiwan facilities.
For more information, please visit the Company's Website at:
www.impaxlabs.com.
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024